Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL30516225

CN1CC(NC(=O)c2cc3nc(-c4ccccc4)cc(N4CCCCC4)n3n2)C1.O=C(O)C(F)(F)F

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 11/20 0.56
HTT P42858 2/20 0.56
ABCB1 P08183 1/20 0.47
HPGD P15428 7/20 0.47
LMNA P02545 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TP53 P04637 3/20 0.47
HSD17B10 Q99714 3/20 0.47
ALDH1A1 P00352 9/20 0.46
MAPT P10636 5/20 0.46
POLB P06746 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
MAPK1 P28482 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GLA P06280 2/20 0.43
GAA P10253 2/20 0.43
RECQL P46063 1/20 0.43
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25969588 0.95 KDM4E (0.62) KDM4EHTTABCB1HPGDLMNA
Trifluoroacetic Acid SCHEMBL31579090 0.94 KDM4E (0.56) KDM4EHTTABCB1HPGDLMNA
Trifluoroacetic Acid SCHEMBL31579036 0.94 KDM4E (0.56) KDM4EHTTABCB1HPGDLMNA
Trifluoroacetic Acid SCHEMBL30516238 0.94 KDM4E (0.56) KDM4EHTTABCB1HPGDLMNA
SCHEMBL25969726 0.89 KDM4E (0.61) KDM4EHTTABCB1HPGDLMNA
SCHEMBL25969729 0.87 KDM4E (0.66) KDM4EHTTABCB1HPGDLMNA
SCHEMBL25338703 0.85 KDM4E (0.60) KDM4EHTTABCB1HPGDLMNA
SCHEMBL25969141 0.81 KDM4E (0.77) KDM4EHTTHPGDLMNASMN1; SMN2
SCHEMBL25970068 0.79 KDM4E (0.57) KDM4EHTTHPGDLMNATP53
SCHEMBL25969590 0.79 PARP1 (0.51) KDM4EHTTABCB1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2025-05-22 US disclosed
EP-4469454-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE Janssen Pharmaceutica NV (BE) 2024-12-04 EP disclosed
WO-2023141866-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161307-A1 PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE SMOX, SRM, SMS KDM4E 1480/4885HTT 3140/4885ABCB1 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.